▁Introduction 10.375
: 6.5234375
<0x0A> 3.994140625
In 4.58203125
▁a 2.93359375
▁significant 7.0078125
▁development 1.8115234375
▁within 6.4140625
▁the 0.3818359375
▁field 3.517578125
▁of 0.0670166015625
▁on 7.5625
colog 2.4140625
ical 0.257568359375
▁research 2.103515625
, 0.193359375
▁Ch 7.421875
iros 9.5625
cience 0.88037109375
▁Group 6.8828125
▁pl 7.51953125
c 0.003246307373046875
▁has 2.236328125
▁announced 1.1875
▁the 0.93115234375
▁init 3.359375
iation 0.00502777099609375
▁of 0.0182647705078125
▁human 4.15625
▁tri 1.4990234375
als 0.00033664703369140625
▁for 1.6416015625
▁two 4.3984375
▁prom 4.10546875
ising 0.0032501220703125
▁anti 3.0390625
- 0.02899169921875
can 0.223876953125
cer 0.00266265869140625
▁comp 2.712890625
ounds 0.005352020263671875
. 1.1982421875
▁This 4.171875
▁p 6.828125
iv 4.26953125
otal 0.0005397796630859375
▁step 2.615234375
▁forward 4.21484375
▁show 9.0546875
cases 0.02557373046875
▁the 0.43212890625
▁company 1.7841796875
' 0.0267486572265625
s 0.001300811767578125
▁commit 1.52734375
ment 0.0013914108276367188
▁to 0.091796875
▁finding 5.02734375
▁innov 2.93359375
ative 0.0167694091796875
▁solutions 1.62890625
▁in 3.40234375
▁the 0.54833984375
▁battle 3.6484375
▁against 0.07611083984375
▁cancer 0.2108154296875
, 2.322265625
▁bol 7.953125
ster 0.0085601806640625
ing 0.4541015625
▁hopes 6.12890625
▁for 0.990234375
▁en 6.453125
hanced 0.118408203125
▁treatment 1.876953125
▁options 1.0166015625
, 3.8515625
▁improved 4.0703125
▁patient 1.0380859375
▁out 0.5673828125
comes 0.0135040283203125
, 0.453125
▁and 0.050140380859375
▁a 1.4716796875
▁br 3.658203125
ighter 0.0004887580871582031
▁future 0.1427001953125
▁in 3.6328125
▁the 0.8125
▁fight 0.8544921875
▁against 0.066650390625
▁this 1.1162109375
▁dev 2.193359375
ast 0.0011005401611328125
ating 0.0032806396484375
▁disease 0.07427978515625
. 0.0494384765625
<0x0A> 0.166015625
Body 10.9765625
: 4.08984375
<0x0A> 2.4375
Ch 1.484375
iros 0.020416259765625
cience 0.002880096435546875
▁Group 1.142578125
▁pl 0.351318359375
c 8.475780487060547e-05
, 1.8046875
▁a 0.65576171875
▁ren 6.28515625
owned 0.0010547637939453125
▁global 3.23828125
▁bi 1.5439453125
oph 1.4072265625
arma 0.0015583038330078125
ce 0.029571533203125
ut 6.9141387939453125e-06
ical 0.00022995471954345703
▁company 0.59423828125
▁with 2.80859375
▁a 0.79345703125
▁strong 2.30859375
▁discipl 10.28125
inary 2.7578125
▁focus 1.4462890625
▁on 0.39599609375
▁scientific 5.89453125
▁research 1.0361328125
▁and 0.6708984375
▁development 0.469482421875
, 0.26611328125
▁has 0.919921875
▁been 3.5546875
▁at 2.716796875
▁the 0.00608062744140625
▁fore 0.05877685546875
front 0.007354736328125
▁of 0.0306396484375
▁cancer 2.7890625
- 3.966796875
related 1.5830078125
▁innov 2.560546875
ations 1.1484375
. 2.240234375
▁With 2.9921875
▁a 0.9482421875
▁strong 2.279296875
▁emphas 3.009765625
is 0.00035262107849121094
▁on 0.017608642578125
▁understanding 5.8125
▁the 0.495849609375
▁bi 2.2578125
ological 1.0380859375
▁mechan 1.30078125
isms 0.002834320068359375
▁that 2.1328125
▁under 0.87646484375
lie 0.63134765625
▁various 3.955078125
▁forms 1.802734375
▁of 0.00809478759765625
▁cancer 0.1866455078125
, 0.272216796875
▁Ch 2.189453125
iros 0.003597259521484375
cience 0.0019388198852539062
▁has 0.9716796875
▁emb 6.70703125
ark 0.06103515625
ed 1.1682510375976562e-05
▁on 0.091796875
▁an 2.26953125
▁ar 4.08203125
du 0.00350189208984375
ous 0.0007605552673339844
▁journey 0.98876953125
▁to 0.7900390625
▁identify 2.97265625
▁effective 3.041015625
▁comp 4.63671875
ounds 0.005199432373046875
▁that 0.8447265625
▁could 2.03125
▁revolution 4.7578125
ize 0.152587890625
▁cancer 1.8623046875
▁treatment 0.496826171875
▁parad 5.31640625
ig 1.2755393981933594e-05
ms 0.005573272705078125
. 0.469482421875
<0x0A> 0.5380859375
Under 5.29296875
▁the 0.66650390625
▁guidance 1.982421875
▁of 0.0408935546875
▁a 2.26953125
▁dedicated 2.404296875
▁team 0.52392578125
▁of 0.08612060546875
▁mult 6.83203125
id 0.1019287109375
is 0.0041656494140625
cipl 0.00018584728240966797
inary 0.0034236907958984375
▁research 1.1484375
ers 0.16162109375
, 0.474365234375
▁Ch 0.78857421875
iros 0.002613067626953125
cience 0.0013685226440429688
▁has 0.340576171875
▁successfully 2.626953125
▁gar 8.71875
ner 1.9073486328125e-05
ed 0.0001214742660522461
▁attention 6.03125
▁through 3.96875
▁its 0.61767578125
▁recent 4.5078125
▁announ 1.291015625
cement 0.058074951171875
▁of 0.59765625
▁the 1.21484375
▁init 0.299560546875
iation 9.85860824584961e-05
▁of 0.00196075439453125
▁human 0.54248046875
▁tri 0.1617431640625
als 5.7220458984375e-06
▁for 0.10418701171875
▁two 0.12066650390625
▁anti 2.203125
- 0.0010242462158203125
can 0.007411956787109375
cer 0.0002067089080810547
▁comp 0.078369140625
ounds 0.0009984970092773438
. 0.591796875
▁These 1.6953125
▁comp 1.7626953125
ounds 0.0012454986572265625
, 0.90966796875
▁met 8.1953125
icul 3.140625
ously 0.005340576171875
▁selected 2.92578125
▁based 2.2734375
▁on 0.008880615234375
▁prom 3.884765625
ising 0.0013189315795898438
▁pre 1.9560546875
- 1.66015625
cl 0.00762176513671875
in 1.4662742614746094e-05
ical 0.0006022453308105469
▁results 1.5107421875
, 0.1798095703125
▁hold 4.3125
▁the 1.068359375
▁potential 0.89892578125
▁to 0.07464599609375
▁significantly 2.435546875
▁impact 1.462890625
▁the 0.487548828125
▁lives 1.662109375
▁of 0.010498046875
▁cancer 0.87158203125
▁patients 0.032012939453125
▁glob 4.76171875
ally 5.4717063903808594e-05
. 0.41943359375
<0x0A> 0.301025390625
Wh 4.88671875
ile 0.032867431640625
▁Ch 2.921875
iros 0.004390716552734375
cience 0.0011320114135742188
▁has 1.125
▁been 1.9130859375
▁relatively 6.68359375
▁tight 8.0859375
- 0.0321044921875
li 0.0027065277099609375
pped 0.00014138221740722656
▁about 0.65380859375
▁the 0.33251953125
▁specific 2.0390625
s 0.57958984375
▁of 0.104248046875
▁the 1.10546875
▁comp 3.0703125
ounds 0.05224609375
▁under 2.189453125
▁investigation 1.703125
, 0.058837890625
▁it 1.4609375
▁is 1.388671875
▁evident 4.06640625
▁that 0.33642578125
▁the 1.099609375
▁company 1.3046875
' 1.76171875
s 0.0002008676528930664
▁scientific 4.56640625
▁pro 4.00390625
w 0.001361846923828125
ess 9.655952453613281e-05
▁and 1.3037109375
▁dil 5.33203125
igent 1.4541015625
▁research 0.908203125
▁have 2.4375
▁led 1.9287109375
▁to 0.1666259765625
▁the 0.63037109375
▁identification 1.6513671875
▁of 0.023895263671875
▁prom 1.8818359375
ising 0.00024700164794921875
▁candidates 2.73828125
. 1.9462890625
▁These 2.326171875
▁comp 0.92626953125
ounds 0.0005021095275878906
, 1.7685546875
▁designed 5.3671875
▁to 0.169921875
▁target 1.2431640625
▁specific 1.400390625
▁mole 2.3515625
cular 0.065673828125
▁path 0.9853515625
ways 0.0017690658569335938
▁within 4.18359375
▁cancer 0.93603515625
▁cells 0.0885009765625
, 0.07403564453125
▁hold 2.658203125
▁the 0.44482421875
▁promise 1.525390625
▁of 0.15380859375
▁over 6.23046875
coming 0.04486083984375
▁critical 5.03125
▁obst 1.763671875
acles 0.0003192424774169922
▁faced 4.04296875
▁by 0.0775146484375
▁conventional 2.021484375
▁cancer 0.8017578125
▁treat 0.82763671875
ments 3.170967102050781e-05
. 0.62353515625
<0x0A> 0.254638671875
Ch 2.24609375
iros 0.01377105712890625
cience 0.001392364501953125
' 1.3798828125
s 0.0017690658569335938
▁CE 4.734375
O 0.0006785392761230469
, 0.27099609375
▁Dr 1.6953125
. 0.12744140625
▁Em 6.45703125
ily 2.203125
▁Carter 7.0234375
, 0.212646484375
▁expressed 2.8828125
▁her 0.64892578125
▁enthus 2.53515625
ias 0.005584716796875
m 2.09808349609375e-05
▁for 1.2109375
▁the 0.23779296875
▁human 4.80859375
▁trial 2.078125
▁phase 4.9375
, 1.2509765625
▁stating 0.87255859375
, 0.91357421875
▁" 0.08251953125
Th 2.9296875
ese 0.016876220703125
▁anti 4.34765625
- 0.0007495880126953125
can 0.006259918212890625
cer 0.0018854141235351562
▁comp 0.179443359375
ounds 0.0007052421569824219
▁represent 2.380859375
▁the 1.8359375
▁cul 1.3447265625
min 0.00022220611572265625
ation 0.0011196136474609375
▁of 0.0007810592651367188
▁years 1.642578125
▁of 0.00726318359375
▁t 6.19921875
ire 0.0838623046875
less 0.0017910003662109375
▁efforts 3.77734375
▁in 3.552734375
▁our 2.35546875
▁labor 2.12890625
ator 0.3486328125
ies 9.775161743164062e-06
. 1.314453125
▁We 1.07421875
▁firm 6.51953125
ly 3.695487976074219e-05
▁believe 0.00460052490234375
▁that 0.18896484375
▁they 1.4658203125
▁possess 4.18359375
▁the 0.458740234375
▁potential 0.451171875
▁to 0.01346588134765625
▁make 2.986328125
▁a 0.1102294921875
▁substantial 3.994140625
▁difference 1.3701171875
▁in 0.472412109375
▁the 0.27490234375
▁lives 0.70361328125
▁of 0.00566864013671875
▁cancer 0.60986328125
▁patients 0.006053924560546875
, 1.841796875
▁sh 7.40625
ifting 0.437255859375
▁the 0.2303466796875
▁parad 0.370361328125
ig 1.2993812561035156e-05
m 0.051727294921875
▁of 0.72216796875
▁treatment 1.9375
▁towards 3.88671875
▁more 0.98046875
▁target 1.2001953125
ed 0.006267547607421875
, 1.48046875
▁effective 1.232421875
, 0.37890625
▁and 0.0208587646484375
▁personal 1.494140625
ized 0.0152435302734375
▁ther 2.046875
ap 0.08551025390625
ies 5.9604644775390625e-06
." 0.38525390625
<0x0A> 0.04913330078125
The 2.111328125
▁comm 6.79296875
enc 0.0135498046875
ement 7.665157318115234e-05
▁of 0.0014410018920898438
▁human 0.4990234375
▁tri 0.06475830078125
als 4.172325134277344e-06
▁is 1.990234375
▁a 0.85888671875
▁critical 3.57421875
▁mil 0.603515625
estone 4.6372413635253906e-05
▁for 0.84521484375
▁Ch 0.450439453125
iros 0.00199127197265625
cience 0.0002677440643310547
▁Group 2.623046875
▁pl 0.10479736328125
c 1.7762184143066406e-05
, 0.49609375
▁mark 3.375
ing 1.7404556274414062e-05
▁the 1.0810546875
▁transition 5.08203125
▁from 0.29736328125
▁pre 1.744140625
- 0.385498046875
cl 0.00800323486328125
in 1.4543533325195312e-05
ical 0.0014324188232421875
▁success 6.23828125
▁to 0.64599609375
▁real 3.724609375
- 0.07733154296875
world 0.0899658203125
▁application 1.58203125
. 0.271240234375
▁The 1.3544921875
▁human 3.99609375
▁trial 0.61181640625
▁phase 0.45556640625
▁will 0.98828125
▁offer 4.30078125
▁in 4.1875
valu 0.03790283203125
able 2.8014183044433594e-05
▁ins 0.9951171875
ights 2.3365020751953125e-05
▁into 0.1148681640625
▁the 0.0965576171875
▁comp 2.318359375
ounds 0.07177734375
' 0.0518798828125
▁effic 0.5224609375
acy 2.3484230041503906e-05
, 1.359375
▁to 3.58203125
x 0.480712890625
icity 9.119510650634766e-05
, 0.46142578125
▁and 0.288818359375
▁potential 2.12109375
▁side 0.7880859375
▁effects 0.0882568359375
▁when 6.84375
▁admin 0.591796875
ister 4.506111145019531e-05
ed 0.0006365776062011719
▁to 0.39453125
▁actual 5.10546875
▁cancer 1.134765625
▁patients 0.01180267333984375
, 2.728515625
▁ultimately 3.71875
▁determ 3.732421875
ining 1.895427703857422e-05
▁their 1.119140625
▁suit 1.078125
ability 0.00023639202117919922
▁for 0.09228515625
▁bro 4.47265625
ader 0.0024127960205078125
▁clin 0.6484375
ical 0.0004267692565917969
▁use 0.85791015625
. 0.03759765625
<0x0A> 0.2410888671875
S 5.24609375
cient 2.501953125
ists 1.890625
▁and 2.0859375
▁research 0.92822265625
ers 0.0221099853515625
▁world 3.25
wide 0.01094818115234375
▁are 1.1005859375
▁eager 2.125
ly 0.161376953125
▁monitoring 6.34375
▁Ch 1.998046875
iros 0.002239227294921875
cience 0.0004868507385253906
' 0.148681640625
s 0.00027179718017578125
▁ground 6.3984375
bre 0.2464599609375
aking 3.635883331298828e-05
▁efforts 3.26171875
, 1.185546875
▁acknowled 5.17578125
ging 0.0013685226440429688
▁the 0.47412109375
▁ur 6.21484375
gent 0.477294921875
▁need 0.03851318359375
▁for 0.498779296875
▁novel 2.068359375
▁th 3.02734375
era 3.6954879760742188e-06
pe 6.556510925292969e-06
ut 1.3709068298339844e-05
ic 0.6484375
▁options 1.208984375
▁in 1.056640625
▁the 0.1544189453125
▁fight 0.64697265625
▁against 0.001312255859375
▁cancer 0.051605224609375
. 0.11236572265625
▁The 1.6669921875
▁potential 5.12109375
▁success 4.046875
▁of 0.055389404296875
▁these 0.73681640625
▁human 4.515625
▁tri 0.040618896484375
als 1.5497207641601562e-06
▁could 3.162109375
▁potentially 5.04296875
▁p 2.88671875
ave 0.0007915496826171875
▁the 0.002574920654296875
▁way 0.00982666015625
▁to 4.41796875
▁a 1.5439453125
▁new 1.15234375
▁era 0.259033203125
▁of 0.291015625
▁cancer 1.005859375
▁treatment 0.35888671875
, 0.4677734375
▁offering 1.83203125
▁hope 0.97119140625
▁to 0.6640625
▁count 1.8818359375
less 6.9141387939453125e-06
▁individuals 3.03125
▁impact 4.32421875
ed 4.0650367736816406e-05
▁by 0.002231597900390625
▁this 0.317626953125
▁disease 2.08984375
. 0.0821533203125
<0x0A> 0.15283203125
Con 5.85546875
clusion 0.5966796875
: 0.1712646484375
<0x0A> 1.0146484375
Ch 1.189453125
iros 0.005069732666015625
cience 0.0004317760467529297
▁Group 0.689453125
▁pl 0.0667724609375
c 3.528594970703125e-05
' 1.9873046875
s 0.0010986328125
▁recent 1.6728515625
▁announ 0.2264404296875
cement 0.002788543701171875
▁regarding 2.6328125
▁the 0.390380859375
▁init 0.2412109375
iation 8.511543273925781e-05
▁of 0.0007834434509277344
▁human 0.09344482421875
▁tri 0.036163330078125
als 2.384185791015625e-07
▁for 0.1314697265625
▁two 0.11199951171875
▁prom 0.9462890625
ising 7.021427154541016e-05
▁anti 0.0193023681640625
- 0.0006051063537597656
can 0.0013036727905273438
cer 0.00018393993377685547
▁comp 0.00620269775390625
ounds 0.0004563331604003906
▁has 2.55078125
▁generated 2.34375
▁optim 4.90234375
ism 0.04656982421875
▁and 2.322265625
▁excitement 0.296875
▁within 2.048828125
▁the 0.0213165283203125
▁scientific 0.64794921875
▁community 0.10723876953125
. 0.1717529296875
▁As 4.453125
▁profession 10.7265625
als 0.0010585784912109375
▁across 3.03125
▁the 0.2364501953125
▁glo 0.6630859375
be 2.9087066650390625e-05
▁eager 4.02734375
ly 0.0006680488586425781
▁await 0.2347412109375
▁the 0.279296875
▁outcome 1.2294921875
▁of 0.049652099609375
▁these 0.36865234375
▁tri 0.40673828125
als 2.6226043701171875e-06
, 0.046234130859375
▁the 1.3427734375
▁potential 2.37890625
▁for 1.5986328125
▁a 2.681640625
▁break 1.404296875
through 0.0005364418029785156
▁in 0.177001953125
▁cancer 0.83740234375
▁research 2.28125
▁hang 9.1953125
s 0.001316070556640625
▁in 0.059234619140625
▁the 0.00439453125
▁balance 0.0025177001953125
. 0.0758056640625
▁Ch 3.791015625
iros 0.01422119140625
cience 0.0009822845458984375
' 0.57421875
s 0.00011265277862548828
▁rel 7.16015625
ent 0.00038242340087890625
less 0.0006422996520996094
▁dedic 2.28515625
ation 1.823902130126953e-05
▁to 0.19970703125
▁finding 1.5078125
▁innov 0.689453125
ative 0.0074310302734375
▁solutions 0.073974609375
▁offers 6.9765625
▁a 1.72265625
▁g 0.7763671875
limp 2.126953125
se 2.5033950805664062e-06
▁into 1.9150390625
▁the 0.492919921875
▁future 0.31591796875
, 2.630859375
▁where 1.8232421875
▁cancer 2.634765625
▁treatment 1.234375
▁may 1.7861328125
▁be 1.1357421875
▁po 7.68359375
ised 0.0001308917999267578
▁for 0.63720703125
▁a 0.298095703125
▁transform 5.38671875
ative 0.28955078125
▁le 1.669921875
ap 0.00026154518127441406
, 5.7265625
▁providing 3.2890625
▁renew 5.91015625
ed 0.00029778480529785156
▁hope 0.020355224609375
▁and 1.8271484375
▁improved 2.955078125
▁out 0.79248046875
comes 0.034210205078125
▁for 0.1978759765625
▁cancer 1.9951171875
▁patients 0.0159454345703125
▁world 1.12109375
wide 0.0007152557373046875
. 0.01410675048828125
